Role of PKC and CaV1.2 in Detrusor Overactivity in a Model of Obesity Associated with Insulin Resistance in Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Leiria, Luiz O ^a   Sollon, Carolina ^a   Calixto, Marina C ^a   Lintomen, Letícia ^a   Mónica, Fabíola Z ^a   Anhê, Gabriel F ^a   De Nucci, Gilberto ^a   Zanesco, Angelina ^b   Grant, Andrew D ^c   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; AMLODIPINE; CALCIUM CHANNEL CAV1.2; CALCIUM CHANNEL L TYPE; CALCIUM ION; CARBACHOL; GLUCOSE; INSULIN; METFORMIN; PHORBOL DIBUTYRATE; POTASSIUM CHLORIDE; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DIET RESTRICTION; DISEASE ASSOCIATION; ENZYME ACTIVITY; EPIDIDYMIS FAT; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADIPOSITY; AMLODIPINE; ANIMALS; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHLORIDE; CARBACHOL; DISEASE MODELS, ANIMAL; EPIDIDYMIS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MICE; MICE, INBRED C57BL; MICE, OBESE; MUSCLE CONTRACTION; OBESITY; ORGAN SIZE; PHORBOL 12,13-DIBUTYRATE; POTASSIUM CHLORIDE; PROTEIN KINASE C; THINNESS; URINARY BLADDER, OVERACTIVE;

MUS;

EID: 84868708510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048507     Document Type: Article

References (51)

1. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, (2004) American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433-438.
2. Opie LH, (2007) Metabolic syndrome. Circulation 115: 32-35.
3. Kahn BB, Flier JS, (2000) Obesity and insulin resistance. J Clin Invest 106: 473-481.
4. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, et al. (2004) Intra-abdominal fat is a major determinant of the national Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome. Diabetes 53: 2087-2094.
5. Barton M, Baretella O, Meyer MR, (2012) Obesity and Risk of Vascular Disease: Importance of Endothelium-Derived Vasoconstriction. Br J Pharmacol 165: 591-605.
6. Moul S, McVary KT, (2010) Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 20: 7-12.
7. Kirby MG, Wagg A, Cardozo L, Chapple C, Castro-Diaz D, et al. (2010) Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn 29: 1360-1364.
8. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, et al. (2008) Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 179: 1891-1895.
9. Richter HE, Kenton K, Huang L, Nygaard I, Kraus S, et al. (2010) The impact of obesity on urinary incontinence symptoms, severity, urodynamic characteristics and quality of life. J Urol 183: 622-628.
10. Rohrmann S, Smit E, Giovannucci E, Platz EA, (2005) Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutritional Examination Survey (NHANES III). Int J Obes (Lond) 29: 310-316.
11. Tong YC, Cheng JT, (2007) Alterations of M2,3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J Urol 178: 1537-1542.
12. Lee W, Chien C, Yu H, Lee S, (2008) Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J Urol 179: 2470-2476.
13. Gasbarro G, Lin DL, Vurbic D, Quisno A, Kinley B, et al. (2010) Voiding function in obese and type 2 diabetic female rats. Am J Physiol Renal Physiol 298: F72-77.
14. Galgani J, Ravussin E, (2008) Energy metabolism, fuel selection and body weight regulation. Int J Obes (Lond) 32: S109-119.
15. Rahman NU, Phonsombat S, Bochinski D, Carrion ED, Nunes L, et al. (2007) An animal model to study lower urinary tract and erectile dysfunction: the hyperlipidaemic rat. BJU Int 100: 658-663.
16. Turban S, Hajduch E, (2011) Protein kinase C isoforms: mediators of reactive lipid metabolites in the development of insulin resistance. FEBS Lett 585: 269-274.
17. Yu CL, Chen Y, Cline GW, Zhang DY, Zong HH, et al. (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277: 50230-50236.
18. Chibalin AV, Leng Y, Vieira E, Krook A, Bjornholm M, et al. (2008) Downregulation of diacylglycerol kinase delta contributes to hyperglycemiainduced insulin resistance. Cell 132: 375-386.
19. Itani SI, Ruderman NB, Schmieder F, Boden G, (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I kappa B-alpha. Diabetes 51: 2005-2011.
20. Huster M, Frei E, Hofmann F, Wegener JW (2010) A complex of Ca(V)1.2/PKC is involved in muscarinic signaling in smooth muscle. FASEB J 24, 2651-2659.
21. Leiria L, Mónica FZ, Carvalho F, Claudino MA, Franco-Penteado C, et al. (2011) Functional, morphological and molecular characterization of bladder dysfunction in streptozotocin-induced diabetic mice: Evidence of a role for L-type voltage-operated Ca2+ channels. Br J Pharmacol 163: 1276-1288.
22. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56: 1986-1998.
23. Calixto MC, Lintomen L, Schenka A, Saad MJ, Zanesco A, et al. (2010) Obesity enhances eosinophilic inflammation in a murine model of allergic asthma. Br J Pharmacol 159: 617-625.
24. De Oliveira CF, Nathan LP, Metze K, Moreno H Jr, De Luca IM, et al. (1999) Effect of Ca2+ channel blockers on arterial hypertension and heart ischaemic lesions induced by chronic blockade of nitric oxide in the rat. Eur J Pharmacol 373: 195-200.
25. Shore SA, Williams ES, Zhu M, (2008) No effect of metformin on the innate airway hyperresponsiveness and increased responses to ozone observed in obese mice. J Appl Physiol 105: 1127-33.
26. Lagaud GJ, Randriamboavonjv V, Roul G, Stoclet JC, Andriantsitohaina R, (1999) Mechanism of Ca2+ release and entry during contraction elicited by norepinephrine in rat resistance arteries. Am J Physiol 276: H300-308.
27. Anhê GF, Hirabara SM, Turrer TC, Caperuto LC, Anhê FF, et al. (2007) Postpartum glycemic homeostasis in early lactating rats is accompanied by transient and specific increase of soleus insulin response through IRS2/AKT pathway. Am J Physiol Regul Integr Comp Physiol 292: R2225-2233.
28. Hanley AJG, Wagenknecht LE, D'Agostino RB Jr, Zinman B, Haffner SM, (2003) Identification of Subjects with Insulin Resistance and β-Cell Dysfunction Using Alternative Definitions of the Metabolic Syndrome. Diabetes 52: 2740-2747.
29. Richter HE, Burgio KL, Brubaker L, Moalli PA, Markland AD, et al. (2005) Urinary Incontinence Treatment Network. Factors associated with incontinence frequency in a surgical cohort of stress incontinent women. Am J Obstet Gynecol 193: 2088-2093.
30. Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT, Chacko S, (2009) Diabetic bladder dysfunction: current translational knowledge. J Urol 182: S18-26.
31. Parsons JK, Sarma AV, McVary K, Wei JT, (2009) Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 182: S27-S31.
32. Vikram A, Jena G, Ramarao P, (2010) Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br J Pharmacol 161: 1708-1721.
33. Michel MC, Barendrecht MM, (2008) Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther 117: 297-312.
34. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, et al. (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148: 565-578.
35. Ford AP, Cockayne DA, (2011) ATP and P2X purinoceptors in urinary tract disorders. Handb Exp Pharmacol 202: 485-526.
36. Pinna C, Sanvito P, Puglisi L, (2006) Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor from rat with outlet obstruction. Life Sci 79: 1301-1306.
37. Kennedy C, Tasker PN, Gallacher G, Westfall TD, (2007) Identification of atropine and P2X1 receptor antagonist-resistant, neurogenic contractions of the urinary bladder. J Neurosci 27: 845-851.
38. Uchida W, Masuda N, Shirai Y, Shibasaki K, Satoh N, et al. (1994) The role of extracellular Ca2+ in carbachol-induced tonic contraction of the pig detrusor smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 350: 398-402.
39. Masters JG, Neal DE, Gillespie JI, (1999) The contribution of intracellular Ca2+ release to contraction in human bladder smooth muscle. Br J Pharmacol 127: 996-1002.
40. Wegener JW, Schulla V, Lee TS, Koller A, Feil S, et al. (2004) An essential role of Cav1.2 L-type calcium channel for urinary bladder function. FASEB J 18: 1159-1161.
41. Wuest M, Hiller N, Braeter M, Hakenberg OW, Wirth MP, et al. (2007) Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. Eur J Pharmacol 565: 180-189.
42. Frazier EP, Peters SLM, Braverman AS, Ruggieri MR, Michel MC, (2008) Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 377: 449-462.
43. Andersson KE, Arner A, (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84: 935-986.
44. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, et al. (2006) Activation of vascular protein kinase C-β inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 55: 691-698.
45. Nobe K, Yamazaki T, Tsumita N, Hashimoto T, Honda K, (2009) Glucose-dependent enhancement of diabetic bladder contraction is associated with a rho kinase-regulated protein kinase C pathway. J Pharmacol Exp Ther 328: 940-50.
46. Lenasi H, Kohlstedt K, Fichtlscherer B, Mülsch A, Busse R, et al. (2003) Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 59: 844-853.
47. Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, et al. (2004) PKC-θ knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114: 823-827.
48. Stretton C, Evans A, Hundal HS, (2010) Cellular depletion of atypical PKC{lambda} is associated with enhanced insulin sensitivity and glucose uptake in L6 rat skeletal muscle cells. Am J Physiol Endocrinol Metab. 299: E402-412.
49. Lu X, Bean JS, Kassab GS, Rekhter MD, (2011) Protein kinase C inhibition ameliorates functional endothelial insulin resistance and vascular smooth muscle cell hypersensitivity to insulin in diabetic hypertensive rats. Cardiovasc Diabetol 10: 48-59.
50. Lee M, Aronne LJ, (2007) Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 99: 68B-79B.
51. Sena CM, Matafome P, Louro T, Nunes E, Fernandes R, et al. (2011) Metformin restores endothelial function in aorta of diabetic rats. Br J Pharmacol 163: 424-437.